IL-17A-话题@MedSci

#IL-17A#

34篇内容 | 902人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191306, encodeId=5ce82191306e2, content=<a href='/topic/show?id=197e1119450d' target=_blank style='color:#2F92EE;'>#川崎病（KD）#</a> <a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=Arthritis Rheumatol：IL-17家族细胞因子升高：川崎病与其他儿童炎症性疾病区分的关键标志, objectType=article, longId=816041, objectId=addf81604184, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668019396776_4754896.png, objectUrl=/article/show_article.do?id=addf81604184, replyNumber=0, likeNumber=19, createdTime=2024-03-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=addf81604184, moduleTitle=Arthritis Rheumatol：IL-17家族细胞因子升高：川崎病与其他儿童炎症性疾病区分的关键标志, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=addf81604184)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1482929, encodeId=5c091482929cc, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, objectType=article, longId=294569, objectId=656829456957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656829456957, replyNumber=0, likeNumber=50, createdTime=2022-01-25, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656829456957, moduleTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656829456957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482928, encodeId=8d8014829282c, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节, objectType=article, longId=219328, objectId=722021932816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=722021932816, replyNumber=0, likeNumber=37, createdTime=2021-10-28, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=722021932816, moduleTitle=J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=722021932816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482927, encodeId=7daf148292e5f, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, objectType=article, longId=210523, objectId=496421052350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=496421052350, replyNumber=0, likeNumber=39, createdTime=2021-04-28, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=496421052350, moduleTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=496421052350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482926, encodeId=bd5314829260c, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验, objectType=article, longId=203507, objectId=ccd220350e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd220350e2c, replyNumber=0, likeNumber=30, createdTime=2020-11-19, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd220350e2c, moduleTitle=恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd220350e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482925, encodeId=fc99148292507, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善, objectType=article, longId=203363, objectId=1f8720336334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8720336334, replyNumber=0, likeNumber=48, createdTime=2020-11-15, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8720336334, moduleTitle=Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f8720336334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482924, encodeId=ffb11482924f3, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, objectType=article, longId=202989, objectId=b8be20298966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8be20298966, replyNumber=0, likeNumber=35, createdTime=2020-11-08, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8be20298966, moduleTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8be20298966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482923, encodeId=32561482923b7, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, objectType=article, longId=198732, objectId=59fb198e32ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fb198e32ce, replyNumber=0, likeNumber=41, createdTime=2020-08-06, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fb198e32ce, moduleTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59fb198e32ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482922, encodeId=30e5148292239, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=30, createdTime=2020-07-20, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482921, encodeId=191614829213c, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=196068, objectId=36e6196068e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e6196068e4, replyNumber=0, likeNumber=37, createdTime=2020-06-19, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e6196068e4, moduleTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36e6196068e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482920, encodeId=aed8148292056, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=29, createdTime=2020-06-15, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482919, encodeId=23251482919fe, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=48, createdTime=2020-06-06, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482918, encodeId=59ec1482918fb, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应, objectType=article, longId=186528, objectId=ba8f18652830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8f18652830, replyNumber=0, likeNumber=39, createdTime=2020-01-21, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8f18652830, moduleTitle=J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba8f18652830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482917, encodeId=74ed148291e80, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=23, createdTime=2019-12-09, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482916, encodeId=a2c214829166c, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=30, createdTime=2019-10-08, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482915, encodeId=3ae41482915a7, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=32, createdTime=2019-10-07, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482914, encodeId=3ac414829141b, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, objectType=article, longId=178241, objectId=2a911e824102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a911e824102, replyNumber=0, likeNumber=38, createdTime=2019-08-29, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a911e824102, moduleTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a911e824102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482913, encodeId=0c301482913fa, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, objectType=article, longId=173291, objectId=9eb91e32918d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eb91e32918d, replyNumber=0, likeNumber=38, createdTime=2019-06-28, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eb91e32918d, moduleTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eb91e32918d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482912, encodeId=148b14829126c, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平, objectType=article, longId=166550, objectId=e11f166550e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11f166550e5, replyNumber=0, likeNumber=42, createdTime=2019-05-23, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11f166550e5, moduleTitle=Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e11f166550e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482911, encodeId=f6cf1482911ee, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=20, createdTime=2019-04-25, rootId=0, userName=12498bf3m27暂无昵称, userId=0ae57859469, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-17A

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#川崎病（KD）# #IL-17A#

Arthritis Rheumatol：IL-17家族细胞因子升高：川崎病与其他儿童炎症性疾病区分的关键标志

2024-03-06发表于上海

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准

2022-01-25

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节

2021-10-28

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功

2021-04-28

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验

2020-11-19

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善

2020-11-15

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎

2020-11-08

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者

2020-08-06

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎

2020-06-19

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-06-15

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应

2020-01-21

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2019-12-09

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-10-08

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-10-07

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎

2019-08-29

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状

2019-06-28

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平

2019-05-23

12498bf3m27暂无昵称 (审核中...)

前往app查看评论内容

#IL-17A#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-04-25

科室
- - 订阅+
  - 更多科室
工具
服务